Yonsei Med J.  2015 Nov;56(6):1604-1612. 10.3349/ymj.2015.56.6.1604.

The Impact of CDH13 Polymorphism and Statin Administration on TG/HDL Ratio in Cardiovascular Patients

• Choi JR
• Jang Y
• Kim Yoon S
• Park JK
• Sorn SR
• Park MY
• Lee M

• KMID: 2345889
• DOI: http://doi.org/10.3349/ymj.2015.56.6.1604

Abstract

PURPOSE
Adiponectin is expressed in adipose tissue, and is affected by smoking, obesity, and genetic factors, such as CDH13 polymorphism, contributing to the development of coronary vascular diseases (CVDs).
MATERIALS AND METHODS
We investigated the effect of genetic variations of CDH13 (rs3865188) on blood chemistry and adiponectin levels in 345 CVD patients undergoing statin-free or statin treatment.
RESULTS
Genetic variation in CDH13 was significantly correlated with several clinical factors, including adiponectin, diastolic blood pressure, triglyceride (TG), and insulin levels. Subjects with the T allele (mutant form) had significantly lower adiponectin levels than those with the A allele. Total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), TG/high-density lipoprotein cho-lesterol (HDLc) ratio, and HDL3b subtype were markedly decreased in statin treated subjects regardless of having the A or T allele. TG and TG/HDL in the statin-free group with TT genotype of the rs3865188 was higher than in the others but they were not different in the statin-treated subjects. We observed a significant difference in adiponectin levels between patients with the A and T alleles in the statin-free group; meanwhile, no difference in adiponectin levels was noted in the statin group. Plasma levels of other cytokines, leptin, visfatin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), were not different among the CDH13 genotypes according to statin administration. Body mass index (BMI), TG, insulin, HDL3b, and TG/HDL ratio showed negative correlations with adiponectin levels.
CONCLUSION
Plasma adiponectin levels and TG/HDL ratio were significantly different according to variants of CDH13 and statin administration in Korean patients with CVD.

Keyword

Adiponectin; CDH13; statin; TG/HDL; HDL3b

MeSH Terms

Adiponectin/blood/*genetics
Adult
Aged
Alleles
Blood Pressure/genetics
Body Mass Index
Cadherins/blood/*genetics
Cholesterol
Cholesterol, LDL
Female
Genotype
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Insulin
Interleukin-6
Leptin/genetics
Lipoproteins, HDL/genetics
Male
Middle Aged
Obesity/blood
Polymorphism, Genetic
Triglycerides/genetics
Tumor Necrosis Factor-alpha/genetics
Vascular Diseases/*drug therapy
Adiponectin
Cadherins
Cholesterol
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Insulin
Interleukin-6
Leptin
Lipoproteins, HDL
Triglycerides
Tumor Necrosis Factor-alpha

Figure

• 

  Fig. 1 Plasma levels of adiponectin (A), TG/HDL (B), LDLc (C), HDL3b (D) subtypes according to CDH13 genotypes whether the stain was taken or not. Values with different alphabets are significantly different among the CHD13 gene genotypes. TG, triglyceride; HDL, high-density lipoprotein; LDLc, low-density lipoprotein cholesterol.

• 

  Fig. 2 Correlation of adiponectin and clinical variables according to genotype distribution of rs3865188. Body mass index (BMI) was negatively correlated with adiponectin in only the AA genotype (p=0.009) in contrast to the TT genotype in statin group; meanwhile, AT genotype can be offset by TT genotype, compared to AA and TT genotype (A and B). Plasma adiponectin was related with TG in A allele of patients taking statin (C and D), and it was related with TG/HDL ratio in the AT genotype in statin-free group. However, with statin treatment, the effect of AT genotype disappeared (E and F). TG, triglyceride; HDL, high-density lipoprotein.

Reference

1. Orlik B, Madej P, Owczarek A, Skałba P, Chudek J, Olszanecka-Glinianowicz M. Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2014; 81:529–535.

2. Nakamura Y, Ueshima H, Okuda N, Miura K, Kita Y, Okamura T, et al. Relation of Serum Leptin and Adiponectin Level to Serum C-Reactive Protein: The INTERLIPID Study. Int J Vasc Med. 2013; 2013:601364.

3. Morisaki H, Yamanaka I, Iwai N, Miyamoto Y, Kokubo Y, Okamura T, et al. CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Hum Mutat. 2012; 33:402–410.

4. Kasahara DI, Williams AS, Benedito LA, Ranscht B, Kobzik L, Hug C, et al. Role of the adiponectin binding protein, T-cadherin (cdh13), in pulmonary responses to subacute ozone. PLoS One. 2013; 8:e65829.

5. Uetani E, Tabara Y, Kawamoto R, Onuma H, Kohara K, Osawa H, et al. CDH13 genotype-dependent association of high-molecular weight adiponectin with all-cause mortality: the J-SHIPP study. Diabetes Care. 2014; 37:396–401.

6. Mavroconstanti T, Johansson S, Winge I, Knappskog PM, Haavik J. Functional properties of rare missense variants of human CDH13 found in adult attention deficit/hyperactivity disorder (ADHD) patients. PLoS One. 2013; 8:e71445.

7. Fredette BJ, Miller J, Ranscht B. Inhibition of motor axon growth by T-cadherin substrata. Development. 1996; 122:3163–3171.

8. Rubina K, Kalinina N, Potekhina A, Efimenko A, Semina E, Poliakov A, et al. T-cadherin suppresses angiogenesis in vivo by inhibiting migration of endothelial cells. Angiogenesis. 2007; 10:183–195.

9. Kyriakakis E, Philippova M, Joshi MB, Pfaff D, Bochkov V, Afonyushkin T, et al. T-cadherin attenuates the PERK branch of the unfolded protein response and protects vascular endothelial cells from endoplasmic reticulum stress-induced apoptosis. Cell Signal. 2010; 22:1308–1316.

10. Philippova M, Ivanov D, Joshi MB, Kyriakakis E, Rupp K, Afonyushkin T, et al. Identification of proteins associating with glycosylphosphatidylinositol-anchored T-cadherin on the surface of vascular endothelial cells: role for Grp78/BiP in T-cadherin-dependent cell survival. Mol Cell Biol. 2008; 28:4004–4017.

11. Chung CM, Lin TH, Chen JW, Leu HB, Yang HC, Ho HY, et al. A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes. 2011; 60:2417–2423.

12. He GX, Tan W. High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention. J Geriatr Cardiol. 2013; 10:355–360.

13. Nusca A, Melfi R, Patti G, Sciascio GD. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. Future Cardiol. 2010; 6:579–589.

14. Chung SD, Tsai MC, Lin HC, Kang JH. Statin use and clinical outcomes among pneumonia patients. Clin Microbiol Infect. 2014; 20:879–885.

15. Vrablík M, Hubáček JA, Dlouhá D, Lánská V, Rynekrová J, Zlatohlávek L, et al. Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res. 2012; 61:609–617.

16. Lee M, Jang Y, Kim K, Cho H, Jee SH, Park Y, et al. Relationship between HDL3 subclasses and waist circumferences on the prevalence of metabolic syndrome: KMSRI-Seoul Study. Atherosclerosis. 2010; 213:288–293.

17. Sull JW, Kim HJ, Yun JE, Kim G, Park EJ, Kim S, et al. Serum adiponectin is associated with family history of diabetes independently of obesity and insulin resistance in healthy Korean men and women. Eur J Endocrinol. 2009; 160:39–43.

18. Jee SH, Sull JW, Lee JE, Shin C, Park J, Kimm H, et al. Adiponectin concentrations: a genome-wide association study. Am J Hum Genet. 2010; 87:545–552.

19. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004; 101:10308–10313.

20. Su TC, Chien KL, Jeng JS, Chen MF, Hsu HC, Torng PL, et al. Age- and gender-associated determinants of carotid intima-media thickness: a community-based study. J Atheroscler Thromb. 2012; 19:872–880.

21. Org E, Eyheramendy S, Juhanson P, Gieger C, Lichtner P, Klopp N, et al. Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet. 2009; 18:2288–2296.

22. Lee JH, Shin DJ, Park S, Kang SM, Jang Y, Lee SH. Association between CDH13 variants and cardiometabolic and vascular phenotypes in a Korean population. Yonsei Med J. 2013; 54:1305–1312.

23. Gao H, Kim YM, Chen P, Igase M, Kawamoto R, Kim MK, et al. Genetic variation in CDH13 is associated with lower plasma adiponectin levels but greater adiponectin sensitivity in East Asian populations. Diabetes. 2013; 62:4277–4283.

24. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002; 87:2764–2769.

25. Song B, Wang Y, Zhao X, Liu L, Wang C, Wang A, et al. Association between statin use and short-term outcome based on severity of ischemic stroke: a cohort study. PLoS One. 2014; 9:e84389.

26. Zhou Q, Ruan ZR, Jiang B, Yuan H, Zeng S. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie. 2013; 68:124–128.

27. Lobo SM, Quinto BM, Oyama L, Nakamichi R, Ribeiro AB, Zanella MT, et al. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. Cytokine. 2012; 60:150–156.

28. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1999; 19:1518–1525.

29. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003; 21:315–325.

30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359:2195–2207.

31. Hubacek JA, Dlouha D, Adámkova V, Lanska V, Ceska R, Vrablik M. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuro Endocrinol Lett. 2012; 33:Suppl 2. 22–25.

32. Ivanov D, Philippova M, Antropova J, Gubaeva F, Iljinskaya O, Tararak E, et al. Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochem Cell Biol. 2001; 115:231–242.

33. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102:1296–1301.